Lysophosphatidic acid (LPA) is a lipid mediator that acts in paracrine systems via interaction with a subset of G protein-coupled receptors (GPCRs). LPA promotes cell growth and differentiation, and has been shown to be implicated in a variety of developmental and pathophysiological processes. At least 6 LPA GPCRs have been identified to date: LPA 1 -LPA 6 . Several studies have suggested that local production of LPA by tissues and cells contributes to paracrine regulation, and a complex interplay between LPA and its receptors, LPA 1 and LPA 4 , is believed to be involved in the regulation of bone cell activity. In particular, LPA 1 may activate both osteoblasts and osteoclasts. However, its role has not as yet been examined with regard to the overall status of bone in vivo. We attempted to clarify this role by defining the bone phenotype of LPA 1 (−/−) mice. These mice demonstrated significant bone defects and low bone mass, indicating that LPA 1 plays an important role in osteogenesis. The LPA 1 (−/−) mice also presented growth and sternal and costal abnormalities, which highlights the specific roles of LPA 1 during bone development. Microcomputed tomography and histological analysis demonstrated osteoporosis in the trabecular and cortical bone of LPA 1 (−/−) mice. Finally, bone marrow mesenchymal progenitors from these mice displayed decreased osteoblastic differentiation. These results suggest that LPA 1 strongly influences bone development both qualitatively and quantitatively and that, in vivo, its absence results in decreased osteogenesis with no clear modification of osteoclasis. They open perspectives for a better understanding of the role of the LPA/LPA 1 paracrine pathway in bone pathophysiology.
Introduction
The identification of the mechanisms that promote skeletal growth and bone formation has significant implications in pathophysiology and medicine. Building up adequate bone mass, potentially influenced by genetic factors during development, is essential for a healthy skeleton and subsequent minimal fracture incidence throughout life [1] . With the help of animal models, there is increasing evidence that local molecular factors strongly influence the building up of bone mass through induction and regulation of osteoblast proliferation and differentiation. Lysophosphatidic acid (LPA) is a potent lipid mediator that acts in paracrine systems via interaction with a subset of G protein-coupled receptors (GPCRs). Based on the recently revised international nomenclature, 6 GPCRs have been identified to date for LPA, LPA 1 -LPA 6 [2] . LPA may be present in the systemic circulation in micromolar concentrations, numerous studies having demonstrated that the local production of LPA by tissues and cells highly contributes to paracrine regulation [3] [4] [5] . LPA promotes cell growth, motility and differentiation, and has been shown to be implicated in a variety of developmental and pathophysiological processes [6] [7] [8] . An increasing interest is attached to the possibility of targeting LPA or LPA receptors for medical purposes [9] .
A complex interplay between LPA and its receptors is believed to be involved in the regulation of osteoblast differentiation and bone formation. Thus, LPA induces proliferation of osteoblasts through a pathway that involves G i proteins and cytosolic calcium [10] [11] [12] as well as osteoclast activation [13] . Lysophosphatidic acid synergistically co-operates with calcitriol to promote maturation of the human osteosarcoma cell line, MG63 [14] . In addition, this study demonstrated the dependence on G i to differentiate mature osteoblasts under LPA. Such an effect of LPA on mature osteoblasts is in agreement with its described role in promoting dendrite outgrowth of the osteocyte-like cell line, MLO-Y4 [15, 16] . LPA induces changes in the cytoskeleton and stimulates the migration of MC3T3-E1 osteoblastic cells [17] . It has also been shown to induce membrane blebbing in mouse primary osteoblasts [18] . Moreover, activation of the P2X7 receptor leads to LPA production and increases mineralization [19] .
As recently demonstrated, LPA 4 inhibits osteoblastic differentiation of stem cells and LPA 4 -deficient mice have increased bone mass [20] . LPA 1 knock-out mice (LPA 1 (−/−) ) exhibit impaired suckling behavior and neurological abnormalities [21] . Nevertheless, the role of the LPA 1 receptor has to this day not been extensively examined with regard to the in vivo bone status.
A key point is that, given the complex actions of LPA 1 on osteogenesis as well as osteoclasis, and the negative role played by LPA 4 on bone mass, the real role of LPA 1 remains elusive. We have attempted to clarify the role of the LPA 1 receptor by defining the bone phenotype of LPA 1 (−/−) mice. This study is to our knowledge the first to document the potential role of LPA 1 in vivo in bone mass and bone development. These mice were studied by microcomputed tomography (μCT) and histological analysis. Finally, bone marrow mesenchymal progenitors from LPA 1 (−/−) mice were tested for proliferation rate and osteoblastic differentiation. The overall results clearly suggest a positive role of LPA 1 in bone development and bone formation, with LPA 1 (−/−) mice presenting decreased bone mass and specific skeletal abnormalities. This may open future perspectives targeting LPA receptors for the control of bone mass.
Materials and methods

Animals and reagents
For this study, the LPA 1 (−/−) mice initially generated by Contos et al.
[ 21] were transferred and maintained in a C57BL/6 background. All data in this study are derived from this strain. Mice were genotyped using PCR analysis of tail or ear DNA to identify homozygous WT (wild-type) or LPA 1 (−/−) mice as previously described [21] . All experiments were performed in accordance with the principles and guidelines established by the French Institute of Medical Research, INSERM, employing the principles and procedures dictated by the highest standards of humane animal care. Growth evaluation was also performed with the initial 129SvJ/C57BL6 and newly generated knock-out mouse strain. Body length (crown-rump distance) was measured at 1, 2 and 4 weeks of age, and femur and tibia lengths were measured at 2 and 4 weeks. All reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA), unless otherwise indicated.
Whole mount alizarin red and alcian blue staining Whole mount skeletal staining was conducted as described previously, with slight modifications [22] . Briefly, mice were anesthetized, eviscerated, skinned, and stained in alcian blue (AB) solution (0.02% AB (w/v), 70% ethanol (v/v), 30% acetic acid (v/v)) for 1 to 2 days at room temperature. Samples were washed through a descending ethanol series, i.e.: 100%, 100%, 95%, 70%, 40%, and 15% ethanol/distilled water (v/v), 1 h each, rinsed twice in distilled water and immerged in distilled water for 1 h. Sample were then treated with 1% (w/v) trypsin, 1 g trypsin digesting 250 g of casein substrate (Invitrogen Molecular Probes, Carlsbad, CA, USA) in 140 mM NaCl solution for 4 h. After rinsing with 140 mM NaCl solution, samples were transferred in 1% (w/v) KOH solution containing 0.1% (w/v) alizarin red S (AR) dye for 24 h at room temperature. Finally, samples were washed through a graded series of 1% (w/v) KOH/glycerol 3/1, 1/1, and 1/3 (v/v), 24 h each, visualized and stored in 100% (v/v) glycerol.
Radiological and histological analysis
Plain radiographs were taken using a soft X-ray apparatus (Softex CMB-2, Softex, Kanagawa, Japan). For histological analysis, some skeletons were fixed in 70°ethanol/distilled water (v/v), embedded in metacrylate and stained with alizarin red according to standard procedures.
High-resolution microcomputed tomography
Femurs and vertebrae of 4-week-old mice were scanned with a high resolution μCT prototype (VivaCT40, Scanco Medical AG, Brüttisellen, Switzerland) as described by Kohlbrenner et al. [23] . At a 3D level, the following calculations were made as previously published [24] : relative bone volume over total bone volume (BV/TV), bone surface over bone volume (BS/BV), trabecular number (Tb.N), trabecular thickness (Tb.Th), trabecular separation (Tb.Sp), and bone mineral density (BMD trab ). Connectivity density (Conn.D) and structure model index (SMI) were calculated without assuming a constant model, as previously described [24] . SMI estimates the platerod characteristics of a structure; its value is 0 for an ideal plate and 3 for an ideal rod, with intermediate values reflecting the volume ratio between rods and plates. The geometric degree of anisotropy (DA) is defined as the ratio between the maximal and minimal radius of the mean intercept length (MIL) ellipsoid. DA reduction is correlated with a more isotropic bone structure.
To analyze the femoral cortex, cross-sectional slices were chosen and the following parameters were calculated: cortical thickness (Ct. Th), cortical area (Ct.Ar), marrow area (Ma.Ar), cross-sectional total area (T.Ar), and cortical bone mineral density (BMD cort ).
Cell cultures
mBMSC (murine bone marrow stromal cells) were obtained from the bone marrow of femurs and tibias of WT and LPA 1 (−/−) mice essentially as described elsewhere [25] . Cells were maintained in modified Eagle medium alpha (αMEM) with 10% (v/v) fetal calf serum (FCS) before use. For proliferation assay, cells were seeded at 20 000 cells per well in 12-well plates and cultured for up to 10 days in a medium consisting of αMEM supplemented with 10% (v/v) FCS. The cells were harvested 2 days after seeding (D0), and later at D3, D7 and D10. For mineralization assays, cells were cultured for up to 14 days in DMEM with 10% FCS (v/v), 100 μM L-ascorbate 2-phosphate as an osteogenic medium (OM) with 10 mM inorganic phosphate essentially as described elsewhere [25] .
DNA assay
Cell layers were washed in PBS, scraped with 0.1% (v/v) NP40 and sonicated. The DNA content was measured using the Picogreen® assay according to the manufacturer's instructions (Invitrogen Molecular Probes, Carlsbad, CA, USA).
Mineralization assay
Calcium deposits from WT and LPA 1 (−/−) cultured cells were stained with 40 mM AR solution, pH = 4.2, as described previously [26] . Briefly, at days 7 and 14 the medium was removed and wells rinsed twice with phosphate buffer saline (PBS). Cells were fixed in 70% ethanol/distilled water (v/v) for 1 h at 4°C. AR solution was added to each well for 5 min and rinsed 7 times in order to remove non-specific staining.
Detection of serum biological markers
In order to evaluate their nutritional and mineral status, WT and LPA 1 (−/−) mice were bled by retro-orbital puncture at 4 weeks. Blood samples were allowed to clot for 30 min and centrifuged for 10 min at 3000 rpm. Levels of serum glucose, iron, albumin, vitamin D, calcium, magnesium, total proteins, phosphorus and CTX-I were measured using conventional enzymatic methods with an Olympus AU400 biochemistry auto-analyzer.
Real time RT-PCR
After removing the bone marrow and grinding the bones, total RNA from WT and LPA 1 (−/−) radius and humerus was isolated using Trisol solution and quantified using an Agilent Ribogreen assay (Invitrogen Molecular Probes, Carlsbad, CA, USA) as described [27] . RNA was reverse transcribed to cDNA using the SuperArray RT2 First Strand kit (Tebu-bio Laboratories, Le Perray en Yvelines, France) according to the manufacturer's instructions. Amplification of the cDNA and detection of the target PCR product were conducted in an ABI Prism 7000 sequence detection system (Applied Biosystems, Carlsbad, CA, USA), using the SuperArray Custom RT2 Profiler PCR Array (Tebu-bio Laboratories, Le Perray en Yvelines, France) according to the manufacturer's instructions. The targets measured included: Col 1, osteocalcin (OC), osterix (OSX), PTHR1 (parathyroid hormone receptor 1), dentin mineral protein 1 (DMP1) and alkaline phosphatase (ALP). RANK (receptor activator of nuclear factor κB), RANKL (RANK ligand), osteoprotegerin (OPG), LPA 2 , LPA 3 , LPA 4 and autotaxin (ATX) primers were purchased from SABiosciences (Frederick, MD, USA). In order to detect LPA 1 expression, forward 5′-ACTGTTAGCACGTGGCTCCT and reverse 3′-GTTGAAAATGGCCCAGAAGA primers were designed with the Primer3 software tool (Biomatters Ltd, Auckland, New Zealand). The RT-PCR results were analyzed using sequence detection software from Applied Biosystems (Carlsbad, CA, USA), and the relative amount of target gene transcript was normalized to the amount of HPRT mRNA control transcript. The data represent results of RNA analyses from 4 different independent experiments obtained with 10 WT and LPA 1 (−/−) mice.
The data shown represent the relative mRNA levels calculated as 2 − ΔCt × 106 where ΔCt = Ctgene of interest − CtHsp90.
Quantification of LPA
After 12 h of fasting, 4-week-old WT and LPA 1 (−/−) mice were bled by retro-orbital puncture and the citrated plasma was carefully centrifuged in order to prevent platelet activation and clotting. LPA was butanolextracted from mouse plasma or bone marrow and quantified using a radioenzymatic assay as described previously [28] . In short, in the presence of [ 
Infrared spectroscopy
Infrared spectra were recorded from KBr pellets on a Nicolet Thermo Avatar 320 FTIR spectrometer between 400 and 4000 cm (corresponding to the phosphate vibrations of the apatite phase) in order to determine the degree of mineralization of the bone tissue [29, 30] .
Statistical analysis
Results are expressed as means ± (SD). Groups were compared using Mann-Whitney analyses as appropriate. A p value b0.05 was considered statistically significant.
Results
Skeletal development is altered in LPA 1 (−/−) mice
Skeletal preparations of 4-week-old mice stained with alcian blue and alizarin red showed homogeneous dwarfism in LPA 1 (−/−) mice, as previously described [21] (Fig. 1A) . LPA 1 (−/−) mice also displayed previously described cranial deformities including shorter snouts and more widely spaced eyes compared with control siblings. Strikingly, 100% of the LPA 1 (−/−) mice analyzed also displayed rib cage deformity.
All mice presented several sterno-distal rib fusions (Fig. 1A , close-up). However, the abnormal patterning was not specific to a single pair of ribs and sometimes affected two consecutive costal elements. In addition, the sternebrae, or segments of the sternum, of LPA 1
mice were shorter, crooked and thicker. Some were even triangular, and the number (normally 7) was typically reduced to 6. The sternum thus appeared sinusoidal (Fig. 1A , close-up), suggesting that the LPA 1 receptor plays a role in the development of sternal cartilage and bone. However, the 1st and 2nd sterno-distal ribs were unaffected. The number and shape of ribs were normal in the proximal and vertebrodistal parts of the dorsal segment. Taken together, these observations suggest that the ventral mesenchymal and costo-vertebral connections are altered due to the absence of LPA 1 . Dorsal ossification of the ribs does not appear to be affected. Most interestingly, we observed delayed vertebral calcification and closure in the thoracic spine of LPA 1 (−/−) mice at 2 weeks of age (Fig. 1B, arrow) . Complete ossification was however achieved 2 weeks later. All vertebral extremities remained thicker in the 4-week-old LPA 1 (−/−) mice (blue stain, Fig. 1A , arrow), also indicating growth plate immaturity. Thus, the overall phenotype of LPA 1 (−/−) mice indicates that LPA 1 plays a role in the processes of skeletal development, especially those involving sternocostal and vertebral elements.
LPA 1 (−/−) mice exhibit abnormal growth LPA 1 (−/−) mice were described as having short snouts and small heads in the original study [21] . Radiographic analysis of 4-week-old LPA 1 (−/−) mice confirmed this craniofacial phenotype (Fig. 1C) (Fig. 1E) . The difference remained significant at 4 weeks of age (Fig. 1E ). No differences in lengths were observed between males and females at any stage. Lower mineral content was also apparent in the femur and tibia of LPA 1 (−/−) mice at 4 weeks, especially in cortical bone (Figs. 1E, left) . The profile X-ray analysis of the LPA 1 (−/−) mice suggested decreased mineralization of the upper part of the spine (Fig. 1C) . Altogether, the skeletal abnormalities of the ribs, limbs and vertebrae, and the lower mineral content observed were highly suggestive of altered ossification in LPA 1 (−/−) mice.
LPA 1 (−/−) mice display decreased vertebral and femoral trabecular bone
The bone phenotype of LPA 1 (−/−) mice was further characterized by μCT analysis at 4 weeks of age. The findings of examination of vertebral and femoral microarchitecture are illustrated in Fig. 2 . Measurements demonstrated a dramatically decreased bone volume over total volume (BV/TV) value in the trabecular bone of the vertebrae and femurs (81%, p = 0.008 and 77%, p = 0.009, respectively) (Figs. 2A, B, and C) . This was essentially due to a reduction in trabecular number and thickness. Decreased connectivity and increased trabecular spacing were also observed (Fig. 2C) . Similar changes were observed in the proximal femurs of LPA 1 (−/−) mice, with a 62% reduction of BV/TV (p =0.05) and a 58% decrease in trabecular number (p =0.05) (Fig. 2C) . SMI was higher in LPA 1 (−/−) mice, indicative of a rod-like structure. Altogether, these results demonstrated significantly decreased bone mass in the vertebral and femoral trabecular bone of LPA 1 (−/−) mice. Alizarin red quantification of mineralized tissue in the proximal tibia also demonstrated a 30% decrease in LPA 1 (−/−) mice (n= 6, p b 0.002) (Fig. 2D) .
The cortical bone of LPA 1 (−/−) mice also showed a 32% reduction in thickness (Figs. 3A and B) . Cortical area (Ct.Ar) was significantly decreased by 37%, with marrow area (Ma.Ar) remaining unchanged (Fig. 3B) . The overall result of μCT studies demonstrated decreased bone mass in LPA 1 (−/−) mice in both trabecular and cortical bone.
Material bone mineral density is not altered in LPA 1 (−/−) mice
Altered bone density as observed by X-ray analysis may be variably due to defective mineralization (osteomalacia) and/or decreased bone mass (osteoporosis). The degree of mineralization of a given volume of bone (material density) [31] can, in first approach, be appreciated by μCT analysis. As shown in Fig. 4B , the material bone mineral density measured by μCT was not modified in the femoral cortex and vertebral trabecular bone of LPA 1 (−/−) mice.
In order to confirm this result, we measured the mineral content of LPA 1 (−/−) mice by infrared spectroscopy (Figs. 4C and D) . Comparison of the relative intensities of the vibration bands produced by the collagenous phase with those of the mineral phase showed that mineralization of the cortical bone was similar in LPA 1 (−/−) and WT mice (Fig. 4D ). These observations were in agreement with the μCT data, suggesting decreased bone content (osteoporosis) with unchanged mineralization in LPA 1 (−/−) mice. These data precluded the hypothesis that osteomalacia alone could be responsible for the alteration of the bone tissue of LPA 1 (−/−) mice.
Since decreased bone mass and/or mineralization may be secondary to alteration of nutritional status as well as calcium, phosphate, and vitamin D intake, we also investigated nutritional and mineral parameters in 4-week-old LPA 1 (−/−) mice. Glucose, albumin, iron, and total protein plasma levels were similar in LPA 1 (−/−) and WT mice, suggesting that the overall nutritional status of the surviving mice was not different from their WT littermates (Fig. 4A, upper) . Moreover, no differences between LPA 1 (−/−) and WT mice were observed (Fig. 4B, lower), ruling out disturbance of mineral homeostasis as a factor responsible for alteration of the skeletal phenotype.
Expression of osteoblast differentiation markers is decreased in LPA 1
In order to better evaluate the impact of LPA 1 receptor deletion on the transcription of osteoblastic differentiation genes, the RNA levels of several bone markers were quantified by RT-PCR in the radius and femur (Fig. 5A) . Most of the bone formation markers analyzed were decreased. The early indicator of osteoblast differentiation, collagen 1, was significantly decreased by 28% (p = 0.04). Osteocalcin levels were also significantly decreased by 35% (p = 0.02). Other markers of osteoblast differentiation, i.e. osterix, PTHR1 and DMP1, were also decreased in the bone of LPA 1 (−/−) mice, by 20%, 22% and 30%, respectively, but this did not reach significance (Fig. 5A ). Interestingly, the mRNA level of RUNX2 (runt-related transcription factor 2), a transcription factor required for initial mesenchymal stem cell differentiation toward the osteoblastic lineage and acting upstream of osterix, was unchanged in LPA 1 (−/−) mice compared with their WT littermates (data not shown).
Taken together, these data demonstrate that some markers of osteoblastic differentiation, collagen 1 and osteocalcin, are significantly less expressed in LPA 1 (−/−) mouse bones. All markers demonstrated a tendency to decrease, suggesting that the overall osteoblastic differentiation process is altered in LPA 1 (−/−) mice. In order to document the level of remodeling, we also investigated the expression of RANK, RANKL and OPG in WT and LPA 1 (−/−) mouse bones. The mRNA level of these genes was similar in LPA 1 (−/−) mice and WT littermates (Fig. 5B) , indicating that osteoclasis, at least in long bones at this stage of development, is unaffected by the loss of the LPA 1 receptor and is therefore not responsible for the altered bone mass. In keeping with these observations, the serum level of CTX-I, a marker of collagen 1 degradation, was unchanged in LPA 1 (−/−) mice compared with WT littermates (Fig. 5C ).
Other LPA receptors, especially LPA 4 , may influence bone differentiation and bone mass [20] . Expression of LPA receptors was therefore also evaluated by RT-PCR in femurs and tibias of LPA 1 (−/−) mice. Expression of autotaxin (ATX), a major enzyme involved in LPA production, was also quantified. Expression of LPA 2 LPA 3 and LPA 4 and ATX was similar in LPA 1 (−/−) mice and WT littermates (Fig. 5D) . As a control, Fig. 5E demonstrates that, as expected, LPA 1 is expressed in bones of WT mice but not in the LPA LPA 1 (−/−) strain. LPA concentration in plasma did not differ between LPA 1 (−/−) mice and WT littermates (209 (±67) vs 189 (±70) pmol/ml, n = 4, NS, in LPA 1 (−/−) mice and WT littermates respectively (Fig. 5F ).
Absence of LPA 1 therefore seems specifically to influence in vivo bone formation, with no significant effect on bone resorption. In addition, the bone phenotype of LPA 1 (−/−) mice does not seem due to a modified expression of other LPA receptors or a variation of LPA production. 
LPA 1 (−/−) mBMSC exhibit impaired proliferation and differentiation processes in vitro
To further investigate whether the impaired bone formation is the result of defective osteoblast proliferation and differentiation, we cultured murine bone marrow mesenchymal stem cells (mBMSC) from LPA 1 (−/−) and WT mice. The proliferation rate of mBMSC was tested in basal medium with 10% FCS for 3, 7 and 10 days (Fig. 6A) . After decreasing at D3, the DNA content of WT mBMSC increased significantly at D7 and D10. The DNA content was dramatically decreased in LPA 1 (−/−) mBMSC (Fig. 6A) .
The osteoblastic differentiation of WT and LPA 1 (−/−) mBMSC was also tested in osteogenic medium. Alizarin red S staining showed highly decreased mineralization in LPA 1 (−/−) cultured mBMSC (Fig. 6B ).
Discussion
Several in vitro studies have so far demonstrated that LPA is involved both in osteoblastic differentiation [10] [11] [12] 14, 15, 18, 19] and in osteoclast activity [13] . LPA interacts with a set of G-protein-coupled receptors, such as LPA 1 and LPA 4 , which are expressed in bone cells. While LPA 4 , likely associated to increase of cAMP [9] , inhibits osteogenic differentiation [20] , so far available in vitro data strongly suggests that LPA 1 has a possible role in promoting bone formation. The current model in fact supports the hypothesis of LPA production by osteoblasts, possibly promoting both osteoblastic differentiation and osteoclasis [13] . Therefore, the absence of LPA 1 may theoretically contribute to either increase or decrease the overall bone mass. The results presented here demonstrate that LPA 1 (−/−) mice display bone abnormalities and osteoporosis, suggesting a prominent role of LPA 1 in osteogenesis.
The bone developmental abnormalities observed in LPA 1 (−/−) mice affected the ribs and vertebrae. Attachment of the ribs to the sternum was abnormal, with fusion of the ribs observed in all LPA 1 (−/−) mice.
Fused ribs are observed in a variety of conditions, for example disruption of the transcription factor Hoxa-9 which results in fusion of the first and second ribs [32, 33] , and more recent data have described multiple developmental factors involved in rib formation. In particular, Hand2 overexpression resumes some of the abnormalities observed in LPA 1 mice [34] . Nevertheless, absence of the bone morphogenetic proteins BMP-4 and BMP-7 is also responsible for abnormal costo-sternal connections [35] . There is to our knowledge no published data indicating that LPA 1 interferes with such processes and, so far, no identified disease clearly resumes the abnormalities observed in LPA 1 (−/−) mice.
LPA 1 (−/−) mice also demonstrated low trabecular and cortical bone mass. These mice had low trabecular bone volume and decreased trabecular number and thickness, both vertebral and femoral trabecular bones being affected. The altered SMI was also indicative of a potentially fragile network. Femoral cortical thickness was also significantly decreased in LPA 1 (−/−) mice. They were therefore severely affected by a global bone defect, suggestive of osteoporosis. Notably, LPA 1 (+/−) animals were fully exempt from any abnormal bone phenotype, and no significant differences between male and females were observed. Indeed, the growth phenotype, affecting vertebrae and limbs, is suggestive of abnormal endochondral ossification. However cortical thickness was also decreased, suggesting an overall alteration of osteogenesis in the absence of LPA 1 . In accordance with this finding, the decreased expression of early and late markers of osteoblastic differentiation suggests that LPA 1 is significantly involved in bone formation. The findings obtained with cultured mBMSC are consistent with the data observed in vivo. The LPA 1 (−/−) mBMSC demonstrated a highly decreased proliferation rate, in keeping with the effect of LPA 1 (−/−) as a growth factor in osteoblastic models [11, 12] . The decreased mineralization of LPA 1 (−/−) mBMSC suggests that their decreased proliferation also impairs their further mineralization. These results, which show the specific impact of the absence of LPA 1 in bone progenitors, are consistent with previous reports obtained in osteoblastic cell lines [14, 18, 19, 36] . Interestingly, as demonstrated by μCT and infrared analysis, the bone mineral deficiency observed in LPA 1 (−/−) mice seems related to true osteoporosis without a mineralization deficiency as such. The mineral density measured by μCT in both trabecular and cortical bone was not significantly decreased in LPA 1 (−/−) mice. The ratio of mineralized to organic phase measured by infrared analysis, as a reflect of the material bone mineral density, was even slightly higher in the bones of LPA 1 (−/−) mice, which may be indicative of a compensatory mechanism to osteoporosis or alteration of mineralization kinetics as observed in osteogenesis imperfecta [37, 38] . In parallel, the major parameters involved in the overall control of bone mass, including calcium, phosphate, and vitamin D, were not modified in LPA 1 (−/−) mice, nor were nutrition parameters.
Of particular interest is the surprising interplay of the different LPA receptors that are thought to act during osteogenesis and are potentially involved in the regulation of bone mass. Recent studies and our data suggest that LPA 1 and LPA 4 receptors display completely opposite effects on the development of bone mass, with LPA 4 exerting a negative effect [20] and LPA 1 a positive one. LPA 1 has been described as activating several intracellular cascades, namely G i , G q and G 12/13 pathways [6] . The G i pathway is usually associated with an increased proliferation rate and seems involved in osteoblastic proliferation under LPA [11, 12] . Nevertheless, overexpression of the G i pathway has also been recently associated with decreased osteogenesis [39] . Therefore, it can be hypothesized that LPA 1 participation in tuning of the G i pathway is necessary to optimize osteoblastic proliferation and differentiation and eventually osteogenesis.
The effect of LPA 1 on bone resorption has been documented in the bone metastasis process [40] , and a role of the LPA 1 /Gi pathway in osteoclast activation has recently been demonstrated [13] . Here, the overall effect in vivo of LPA 1 was to decrease bone mass and, supposedly, to lower the osteogenesis rate.
Indeed, the potential effect of LPA on osteogenesis or osteoclasis may depend on the respective expression of LPA receptors by bone cells and the concentration of LPA in the tissue. In this view, the potency of specific molecular species of LPA towards LPA 1 and LPA 4 is variable [9] . In parallel, distinct mechanisms may be involved in the control of the paracrine secretion of LPA [3] [4] [5] , several data supporting the hypothesis of LPA production in bone tissue itself [19, 40] . Osteoblasts secrete LPA through activation of phospholipase C and phospholipase A 2 pathways [19] . We also observed that human MSC also produce significant levels of secreted LPA (personal unpublished results). In addition, platelets may contribute to significant increase of the local concentration of LPA in bone tissues [5, 40] . In this view, we found no indication in our study of a modification of either the level of circulating LPA or the expression of autaxin, the main enzyme involved in LPA production, in LPA 1 (−/−) mice.
In parallel, the expression of other LPA receptors was not modified in the bone tissue of LPA 1 (−/−) mice, suggesting that their bone phenotype, and osteoporosis in particular, can be attributed to the absence of LPA 1 alone.
Conclusion
In summary, the results of our study help to clarify the role of LPA 1 in vivo. LPA 1 (−/−) mice display defects in bone formation with osteoporosis as consequence, as well as specific developmental abnormalities, indicating that the LPA 1 receptor is significantly involved in osteogenesis. Notably, the active emergence of therapeutics involving lysophospholipids and their receptors could include bone as a future target of LPA receptor modulation. 
